VIDEO: COAST, ShORe trials aim to replicate superiority demonstrated in phase 2b trial
Click Here to Manage Email Alerts
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Fred Guerard, CEO of Opthea, shares updates on the COAST and ShORe trials.
The phase 3 trials are examining the use of sozinibercept combined with anti-VEGF-A therapies for the treatment of wet age-related macular degeneration.
A randomized, double-masked phase 2b trial with 366 patients demonstrated the superiority of sozinibercept when used in combination with ranibizumab compared with ranibizumab alone.
“We are currently running two large clinical trials that are designed to replicate the superiority that we have demonstrated in this phase 2b trial,” Guerard said. “Each of these trials are around 1,000 patients each, and we’re very excited to see the data when it comes out around the middle of next year.”
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts